Pressure on notified bodies delays important approval for newly-listed Danish blood test firm
Qlife, which recently entered the stock exchange, has delayed the launch of its device for home analysis of blood tests, due to bottlenecks at busy notified bodies. "It is irritating, and not great for us," the CEO says.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
Medtech company Qlife, which entered the stock exchange in Sweden last week, has been forced to delay the launch of its product for home analysis of blood tests, which was planned for the beginning of the year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
